POP Biotechnologies and EuBiologics EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial miamiherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miamiherald.com Daily Mail and Mail on Sunday newspapers.
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19
Cancer patients who continue smoking after their diagnosis have a nearly doubled risk of heart attack, stroke or death due to cardiovascular disease compared with non-smokers, according to research published on World No Tobacco Day in European Heart Journal, a journal of the European Society of Cardiology (ESC).